Medigene AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ralph Schafer
- Full Time Employees
- 87
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Lochhamer Strasse 11 Munich Germany 82152
- IPO Date
- Jun 17, 2013
- Website
- medigene.com
- Similar Companies
- Business
- Medigene AG (FSE: MDG1; OTC: MDGEF), a clinical-stage biotechnology company headquartered in Planegg/Martinsried near Munich, Germany, and founded in 1994, specializes in developing T cell receptor (TCR)-guided immunotherapies for solid tumors and potentially other immune disorders. The company leverages its proprietary End-to-End Platform, which generates optimal affinity 3S TCRs (specificity, sensitivity, safety) applicable across modalities including TCR-T cell therapies, TCR-natural killer cell therapies, TCR-guided T cell engagers (TCR-TCEs), and other bispecific constructs; key pipeline assets encompass MDG1015, a third-generation NY-ESO-1/LAGE-1a-targeted TCR-T therapy combined with the PD1-41BB costimulatory switch protein, alongside programs targeting neoantigens like multiple KRAS mutations and HLAs, and historical dendritic cell vaccines such as FDC101. Operations focus on immuno-oncology research, TCR discovery and optimization, product enhancement technologies like precision pairing libraries, and partnering for clinical validation and commercialization, targeting global patient populations in oncology through collaborations with academic institutions in Europe and North America, including Charité Berlin, Helmholtz Munich, and the National Cancer Institute. Recent developments include the Munich Local Court opening insolvency proceedings for Medigene AG and subsidiary Medigene Immunotherapies GmbH on August 1, 2025; appointment of Ralph Schäfer as sole CEO on July 25, 2025 following the departure of prior leadership; a February 2025 strategic co-development agreement with EpimAb Biotherapeutics for TCR-guided T cell engagers in immune disorders; an August 2024 three-year multi-target partnership with WuXi Biologics for TCR-TCEs against solid tumors, including joint development of MDG3010; a comprehensive research collaboration with BioNTech since 2022 for multiple TCRs against solid tumor targets, with BioNTech acquiring specific assets like TCR-4/PRAME; transition of the MAGE-A4 TCR program to Regeneron Pharmaceuticals via 2seventy bio in April 2024; pipeline prioritization and resource reallocation; an oversubscribed capital raise in May 2024 yielding EUR 5.9 million to extend cash runway into July 2025; and a subsequent Standby Equity Purchase Agreement for up to EUR 15 million.
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.
Medigene AG announces closing of its first SEPA tranche
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024
Medigene AG (MDGEF) Q2 2024 Earnings Call Transcript
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
Medigene AG to Report Half-Year 2024 Financial Results on August 14, 2024
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
Medigene AG reports Financial Results and Business Update for Q1 2024
Medigene AG Secures European Patent for its iM-TCR Technology
Medigene AG (MDGEF) Full Year 2023 Earnings Call Transcript